Key result
Blood levels of miR-216a, miR-377, ANGPTL4, GAP-43, and PPARG were significantly differentially expressed in DPN and demonstrated potential as novel molecular diagnostic markers.
Why the study?
Diabetic peripheral neuropathy lacks effective means for early diagnosis and treatment, and specific research on microRNAs in DPN is rare.
Can blood miR-216a, miR-377, ANGPTL4, GAP-43, and serum PPARG serve as diagnostic biomarkers for diabetic peripheral neuropathy in type 2 diabetes?
Population
Blood samples of patients with DPN
Authors
Loading...
Hypothesis-generating for miR-377 and miR-216a in DPN; validation required before clinical consideration.
Observational
Can blood miR-216a, miR-377, ANGPTL4, GAP-43, and serum PPARG serve as diagnostic biomarkers for diabetic peripheral neuropathy in type 2 diabetes?
Blood levels of miR-216a, miR-377, ANGPTL4, GAP-43, and PPARG show potential as novel molecular diagnostic biomarkers for diabetic peripheral neuropathy.
Li et al. (2021) conducted an observational in Diabetic peripheral neuropathy of Type 2 Diabetes. Blood miR-216a, miR-377, ANGPTL4, GAP-43, and PPARG levels was evaluated on Differential expression and diagnostic utility for DPN. Blood levels of miR-216a, miR-377, ANGPTL4, GAP-43, and PPARG were significantly differentially expressed in DPN and demonstrated potential as novel molecular diagnostic markers.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: